Quantum Cat CVRP Data Sheet

 QUALITATIVE AND QUANTITATIVE COMPOSITION

PHARMACEUTICAL FORM
Lyophilisate and solvent for solution for injection.

CLINICAL PARTICULARS

Target species
Cats from 9 weeks of age.

Indications for use, specifying the target species
Active immunisation of cats to reduce mortality and clinical signs of disease caused by feline enteritis (panleucopenia) virus, to reduce clinical signs of disease caused by feline rhinotracheitis virus and to prevent clinical signs of disease and reduce infection caused by feline calicivirus.

Onset of immunity occurs by approximately 3 weeks after the last dose of the Basic Vaccination Scheme.
The duration of immunity is at least 12 months.

Contra-indications
Do not use in unhealthy animals.

Special warnings for each target species
The feline panleucopenia virus and the feline calicivirus vaccinal strains may be shed from vaccinated animals for a number of days following vaccination.  However, due to the low pathogenicity of these strains, it is not necessary to keep vaccinated animals separated from non-vaccinated animals.
Moderate to high levels of maternally derived antibodies (MDA) may interfere with the response to vaccination.

Special precautions for use
Special precautions for use in animals
None.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of the product literature.

Adverse reactions (frequency and seriousness)
On rare occasions, transient increases in rectal temperature, transient lameness  and transient lethargy may be observed as well as soft painless swellings (<1 cm average) may occur in the first 24 hours after vaccination, which may be evident as painless hard nodules for up to 21 days after dosing.

On very rare occasions, an anaphylactic reaction may occur which may require appropriate symptomatic treatment (eg adrenaline).

When Quantum Cat CVRP and Quantum Cat FeLV are administered simultaneously, incidence of local reactions may be increased.

Use during pregnancy, lactation or lay
Do not use during pregnancy.

Interactions with other medicinal products and other forms of interactions
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Quantum Cat FeLV.  No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product listed above.  A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Amounts to be administered and administration route
Reconstitute the freeze-dried vaccine aseptically with the complete contents of the diluent provided.  Shake and immediately inject the contents of the vial subcutaneously 1 ml per dose.

Basic vaccination
In cats aged nine weeks and over, two injections of Quantum Cat CVRP, 3 to 4 weeks apart will stimulate full active immunity.

Re-vaccination
A single 1 ml dose is required on an annual basis.

If simultaneous immunisation against feline leukaemia virus (FeLV) is required, Quantum Cat CVRP can be reconstituted with Quantum Cat FeLV (inactivated, adjuvanted sub-unit FeLV vaccine) in place of the diluent, using the reconstitution method described above. Once mixed, the vaccines should be injected immediately via the subcutaneous route.

Do not use chemically sterilised syringes or needles, as these might affect the effectiveness of the vaccine.

Overdose (symptoms, emergency procedure, antidotes, if necessary
No reactions other than those listed in Section “Adverse reactions” are observed after an overdose administration.

Withdrawal period(s)
Not applicable.

IMMUNOLOGICAL PROPERTIES
ATC Vet Code – QI06AD04
Vaccination induces the active immunity in healthy cats against feline infectious enteritis (panleucopenia) and respiratory disease due to feline rhinotracheitis virus and calicivirus.

PHARMACEUTICAL PARTICULARS

List of excipients
Water for injections (diluent), Neomycin and Gentamycin.

Incompatibilities
Do not mix with any other veterinary medicinal product except the diluent provided for reconstitution or Quantum Cat FeLV (inactivated, adjuvanted sub-unit FeLV vaccine).

Shelf-life
Shelf life of the veterinary medicinal product as packaged for sale - 2 years.
Shelf life after reconstitution according to directions: Use immediately.

Special precautions for storage
Store and transport the freeze-dried component and the diluent between 2°C and 8°C.  Do not freeze.

Nature and composition of immediate packaging
The freeze-dried component and the liquid component are filled in 1 monodose glass vials Type I (Ph. Eur.).  Both have a rubber stopper fulfilling Ph. Eur. requirements and an aluminium cap.

Cartons contain 25 glass vials of 1 monodose containing the freeze-dried component and 25 glass vials of 1 ml containing the diluent.

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate
Dispose of waste materials by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.

MARKETING AUTHORISATION HOLDER
Intervet UK Ltd
Walton Manor
Walton
Milton Keynes
Bucks MK7 7AJ

MARKETING AUTHORISATION NUMBER
Vm 01708/4557

DATE OF RENEWAL
28 October 2010

DATE OF LAST REVISION OF SPC
December 2010

Legal category
POM-V   To be supplied on veterinary prescription only.
Keep out of the reach and sight of children. For animal treatment only.